Nephrology: Recent Episodes
ReachMD
Guest: Anuja Java, MD
Complement 3 glomerulopathy (C3G) presents complex diagnostic hurdles due to its rarity, clinical heterogeneity, and lack of definitive biomarkers. Tune in to hear Dr. Gates Colbert and Dr. Anuja Java discuss the need for improved biomarker development, our evolving understanding of complement dysregulation, and the importance of multidisciplinary awareness in advancing timely and accurate diagnosis. Dr. Java is an Associate Professor of Medicine in the Division of Nephrology at Washington University School of Medicine and the Director of the Kidney Transplant Clinic at John Cochran Veterans Hospital in Missouri.
Guest: Anuja Java, MD
With the recent approval of iptacopan and promising data on pegcetacoplan emerging, targeted therapy is becoming a reality for patients with complement 3 glomerulopathy (C3G). Hear from Dr. Gates Colbert and Dr. Anuja Java as they dive into the details of newer treatments, key considerations for patient monitoring, and the role of precision medicine in patient care. Dr. Java is an Assistant Professor of Medicine in the Division of Nephrology at Washington University School of Medicine and the Director of the Kidney Transplant Clinic at John Cochran Veterans Hospital in Missouri.
Host: Gates B. Colbert, MD
Guest: Meghan Sise, MD
Guest: Ellie Kelepouris, MD, FACP, FAHA
Early detection of IgA nephropathy (IgAN) is often missed due to its subtle presentation, leading to delays in critical care. However, knowing the red-flag signs and symptoms to look out for can help improve timely diagnosis and intervention. Joining Dr. Gates Colbert to discuss practical strategies for identifying IgAN early are Drs. Meghan Sise and Ellie Kelepouris. Dr. Sise is the Director of Onconephrology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, and Dr. Kelepouris is the Director of the Outpatient Dialysis Program and a Professor of Clinical Medicine at Penn Medicine.
Host: Brian P. McDonough, MD, FAAFP
Guest: Suneel Udani, MD
Over the past several decades, IgA nephropathy (IgAN) has gone from being regarded as relatively harmless to being recognized as a progressive, high-risk disease. With this new understanding, early diagnosis and strategic intervention are more critical than ever. Tune in as Dr. Suneel Udani, a nephrologist with Nephrology Associates of Northern Illinois, joins Dr. Brian McDonough to examine the key factors in detecting and treating IgAN.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Barratt, PhD
New insights into B-cell dysregulation are reshaping our understanding of IgA nephropathy (IgAN), and the BAFF/APRIL pathway in particular is being studied for its role in driving immune complex formation, glomerular injury, and disease progression. Joining Dr. Charles Turck to discuss B-cell dysregulation and its potential impacts on the IgAN treatment landscape is Dr. Jonathan Barratt. Dr. Barratt is the Mayor Professor of Renal Medicine at the University of Leicester in the United Kingdom, where he also leads the Renal Research Group.
Guest: Richard Lafayette, MD, FACP
For patients with C3 glomerulopathy (C3G), supportive care is a critical yet often underemphasized component of disease management. Join Dr. Richard Lafayette as he outlines key strategies to reduce risks, improve quality of life, and empower patients to engage actively in their long-term care. Dr. Lafayette is a Professor of Nephrology and the Director of the Glomerular Disease Center at Stanford University Medical Center in California.
Guest: Gates B. Colbert, MD
When counseling patients with C3 glomerulonephritis (C3GN), an open dialogue, education, and individualized treatment planning are crucial for optimal care. Join Dr. Gates Colbert as he shares practical strategies to foster trust, encourage engagement, and support patients navigating a complex and often unpredictable condition. Dr. Colbert is an Assistant Clinical Professor at Texas A&M College of Medicine and a practicing physician with the Kidney and Hypertension Associates of Dallas, located at Baylor University Medical Center.
Guest: Gates B. Colbert, MD
Managing patients with relapsing or treatment-resistant C3 glomerulopathy (C3GN) often presents significant clinical and emotional challenges. Join Dr. Gates Colbert as he discusses how clinicians can set realistic expectations for patients, collaboratively tailor treatment plans, and mitigate the impacts of itensified treatment regiments on quality of life. Dr. Colbert is a Clinical Assistant Professor at Texas A&M College of Medicine and a practicing physician with Kidney and Hypertension Associates of Dallas at Baylor University Medical Center.
Host: Andreas Kronbichler, MD
Guest: Bernhard Hellmich, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Bernhard Hellmich, MD
Guest: Silke R. Brix, MD, MRCP, SCPR
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Guest: Silke R. Brix, MD, MRCP, SCPR
Host: Andreas Kronbichler, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Silke R. Brix, MD, MRCP, SCPR
Guest: Andreas Kronbichler, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Bernhard Hellmich, MD
Guest: Andreas Kronbichler, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Silke R. Brix, MD, MRCP, SCPR
Guest: Bernhard Hellmich, MD
Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Host: Melissa Magwire, RN, MSN, CDE
Guest: Matthew Bullington, PharmD
Guest: Dawn M. Denicola, FNP-C
Guest: Keith Miller, MD
Are you up to date on the plethora of benefits patients may receive from SGLT2 inhibitors? Learn from a multidisciplinary faculty panel as they use patient case vignettes to review emerging evidence and evolving treatment guidelines related to cardio-renal-metabolic comorbidities such as type 2 diabetes, heart failure, chronic kidney disease, and management of patients post-MI. Tune in for the insights you need to enhance your practice.
Host: Kieran McCafferty, MD
Guest: Maurizio Gallieni, MD
Patients with chronic kidney disease-associated pruritus (CKD-aP) often face delays in diagnosis and treatment, as well as potential side effects from some prescribed medicines. Tune in as our experts dive into the burden of CKD-aP symptoms and break down the long-term outcomes and benefits of new and emerging treatments.
Complement 3 glomerulopathy (C3G) is an ultra-rare kidney disease characterized by overactivation of the alternative complement pathway. This program provides insights into the pathogenesis of the disease.
FA-11319389 12/24
Guest: Donald Kohan, MD, PhD
Increased formation of renal endothelin one is associated with renal injury.1 In several studies, activation of the ETA receptor has been shown to contribute to IgA nephropathy (IgAN) progression, and markers of endothelin system activity are elevated in patients with the disease.2,3-5 Join Dr Donald Kohan as he dives into the latest research on this connection, which could provide insight into new tailored therapy approaches for IgAN patients. Dr Kohan is a nephrologist at University of Utah Health in Salt Lake City.
References:
- Kohan DE, Barton M. Kidney Int. 2014;86(5):896-904. doi:10.1038/ki.2014.143
- Kohan DE et al. Kid Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023
- Lehrke I et al. J Am Soc Nephrol. 2001;12:2321-2329. doi.org/10.1681/ASN.v12112321
- Zanatta CM et al. Ren Fail. 2012;34(3):308-315. doi:10.3109/0886022X.2011.647301
- Tycova I et al. Physiol Res. 2018;67:93-105. doi.org/10.33549/physiolres.933670
FA-11319389 12/24
Host: Mikhail Kosiborod, MD
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their treatment. Join the experts as they explore chronic hyperkalemia management, and the role of potassium binders.
Guest: Rasheed A. Gbadegesin, MD, MBBS
A new study by the H3 Africa Kidney Research Network found that APOL1 variants are a major risk factor for chronic kidney disease. Additionally, these variants are particularly prevalent among West Africans. Dr. Rasheed Gbadegesin dives into these findings and explains how they could contribute to preventive measures and improved outcomes in patients of African ancestry. Dr. Gbadegesin is the Director of the Office of Physician-Scientist Development at Duke University School of Medicine.
Host: Jörg Latus, MD
Guest: Chee Kay Cheung, MBCHB, MRCP, PHD
Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addition, the mechanisms of action of some IgAN therapies may offer advantages over others in targeting specific pathways in disease pathophysiology. Join the experts for an exploration of these important clinical topics using a patient case study.
Guest: Jörg Latus, MD
Patients with advanced kidney disease undergoing dialysis are frequently affected by the symptom clusters of chronic kidney disease-associated pruritus, or CKD-aP. These symptoms have the potential to significantly diminish patients’ quality of life by affecting sleep, mental health, and more. This activity reviews best practices for communicating with patients about symptoms and how to use shared decision-making strategies to develop personalized CKD-aP treatment plans.
Host: Jörg Latus, MD
Guest: Sydney Tang, MBBS, MD
In this review of clinical trial results, experts cover the latest data in IgA nephropathy and discuss how their application can improve outcomes for your patients. Studies presented include SPARTAN, SPARTACUS, and the PROTECT open-label extension. Throughout this conversation, faculty also consider the anticipated updates to the KDIGO clinical guidelines.
Guest: Mohamed Ibrahim, MB, BCh
IgA nephropathy (IgAN) is a rare autoimmune kidney disease in which IgA deposits damage kidney filters, causing symptoms like proteinuria and swelling. While symptoms can overlap with other kidney diseases, IgAN presents challenges of its own. Learn about the unique characteristics of IgAN with Dr. Mohamed Ibrahim, an Assistant Professor of Transplant Nephrology at the University of Maryland School of Medicine.
Guest: Jennifer Moore, MS, RDN, CSR, LDN
Host: Charles Turck, PharmD, BCPS, BCCCP
IgA nephropathy, or IgAN, is a rare kidney disease that requires dietary changes to maintain kidney health and function while supporting other organ systems. Learn about the most crucial dietary considerations for these patients from Jennifer Moore, a renal nutrition expert.
Host: Gates B. Colbert, MD
Guest: Kelly Helm
Over 35 million people in the United States suffer from some form of chronic kidney disease, but many of them lack the support and education to navigate their condition and receive the best possible care. After her daughter was diagnosed with a rare kidney disease, Kelly Helm discovered the many obstacles associated with management and treatment. Hear from Kelly as she sits down with Dr. Gates Colbert to share what she’s learned as a parent, caregiver, and advocate. Kelly is the Executive Director of Patient Engagement at NephCure, a nonprofit organization dedicated to supporting and empowering patients with rare kidney diseases.
Host: Jody Takemoto, PhD
Guest: David Braun
Identifying biomarkers for renal cell carcinoma (RCC) is critical since they can help direct our therapeutic approach, which is why several techniques that may be able to uncover new biomarkers are currently being investigated. Joining Dr. Jody Takemoto to review those techniques and their potential impacts on RCC care is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.
Host: Jody Takemoto, PhD
Guest: David Braun, MD, PhD
A recent study investigated whether renal cell carcinoma (RCC) molecular subtypes have any impact on treatment outcomes. Here to share the surprising findings and their implications is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Ian de Boer, MD
Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it’s essential to know how to proactively diagnose and treat them using the latest therapeutic advances and strategies. Tune in to hear Dr. Mary Katherine Cheeley discuss diabetes management in patients with chronic kidney disease with Dr. Ian de Boer, Professor of Medicine in the Division of Nephrology and the Director of the Kidney Research Institute at the University of Washington in Seattle.
Guest: Vallerie V. McLaughlin, MD
Host: Melisa A. Wilson, DNP, APRN, ACNP, BC
Host: Sarah Kesler, MD
Learn how to use guideline recommendations to establish a diagnosis of pulmonary arterial hypertension (PAH), develop evidence-based individualized treatment plans, and explore innovative therapies under investigation for PAH management. Hear from expert faculty on how to integrate the patient’s perspective when personalizing management plans for PAH.
Host: David Lynch, MB, BCh
Learn about making timely and accurate diagnoses of ILD, review radiologic patterns, and discuss the importance of multidisciplinary care in radiology.
Host: Pietro A. Canetta, MD
Expert Nephrologist Pietro Canetta, MD, MS, gives an overview of top abstracts from Kidney Week 2023 and new therapies for IgAN.
Host: Richard Lafayette, MD, FACP
Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.
Host: Robert F. Kushner, MD
Host: Donna Ryan, MD
Host: Christopher D. Still, DO, FACN, FACP, FTOS
Obesity experts review obesity management strategies and provide insight on best practices for implementation in a primary care setting.
Host: Kathleen Liu MD, PhD, FASN, BRCU
Guest: Jay L. Koyner, MD
In this episode of KDIGO Conversations in Nephrology, Dr. Kathleen Liu is joined by Dr. Jay Koyner to discuss the emerging field of persistent acute kidney injury (AKI). They delve into the question: what exactly is persistent AKI, and how does it differ from severe AKI? Dr. Liu and Dr. Koyner explore the key factors clinicians should consider when evaluating a patient's risk of developing persistent AKI. They also highlight the latest developments in this area of nephrology research, leaving listeners with valuable insights into the diagnosis and management of persistent AKI.
Join us as we discuss:
- What is persistent AKI, and how is it distinguished from severe AKI?
- What clinical factors should be considered when assessing a patient's risk of persistent AKI?
- What are some of the new developments in the field of persistent AKI research?
- How can this knowledge be applied to improve patient care?
This episode is supported by an independent educational grant from Baxter.
Host: Kathleen Liu MD, PhD, FASN, BRCU
Guest: Professor Claudio Ronco
This episode dives into the recent advancements and best practices surrounding Extracorporeal Blood Purification within the complex scenario of multiorgan support. Join Drs. Kathleen Liu and Claudio Ronco as they engage in a thought-provoking discussion, exploring:
- Recent clinical trials suggesting minimal benefits of early CRRT in AKI for critically ill patients. The conversation delves into whether these findings translate to patients experiencing multiorgan failure, exploring the potential differentiating factors.
- The potential of CRRT to extend beyond renal support. The discussion explores how CRRT might offer support to other vital organs in the setting of multiorgan system failure.
- The role of current CRRT technology in eliminating inflammatory mediators. Dr. Ronco sheds light on the capabilities of current technology and its potential impact on the inflammatory response.
Join Dr. Liu and Dr. Ronco for an insightful exploration of extracorporeal blood purification’s evolving role in optimizing care for critically ill patients.
This episode is supported by an independent educational grant from Baxter.
Host: Kathleen Liu MD, PhD, FASN, BRCU
Guest: Kianoush B. Kashani MD, MS, MSc, FASN, FCCP
In this episode, Dr. Kathleen Liu welcomes Dr. Kianoush Kashani to discuss the rising importance of personalized care in Acute Kidney Injury (AKI) treatment. They delve into the world of digital health, exploring how digital decision support tools can empower clinicians and improve patient outcomes.
This episode will address:
- Digital Health: Dr. Kashani breaks down the concept of digital health and its applications in the context of AKI management.
- The Power of Digital Tools: Discover how digital decision support systems can aid clinicians in early detection, risk stratification, and personalized treatment plans for AKI patients.
- Personalized Care for AKI: Dr. Liu and Dr. Kashani explore why a one-size-fits-all approach doesn't work for AKI, and how digital tools can pave the way for individualized care.
- Optimizing KRT Outcomes: Learn how digital health can improve decision-making around KRT, leading to better patient outcomes.
Tune in for this informative discussion on leveraging the power of digital health to personalize AKI care.
This episode is supported by an independent educational grant from Baxter.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Christin Iroegbu PhD, RN
If left untreated, chronic kidney disease (CKD) can progress to end-stage renal disease, requiring dialysis or kidney transplant as the only treatment options. So communicating this to patients, along with chronic conditions that could contribute to this are key. To learn more about raising awareness of the causes of CKD and to help slow the progression, join Dr. Mary Katherine Cheeley who’s speaking with Dr. Iroegbu, Co-Author of the article published in the Journal of Advanced Nursing, titled “An Integrative Review: Chronic Kidney Disease Awareness and the Social Determinants of Health Equity,” and T32 Postdoctoral Research Fellow at the Center for Health Outcomes and Policy Research at the University of Pennsylvania School of Nursing.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Guest: Gates B. Colbert, MD, FASN
A class of medications called SGLT2 inhibitors have been proven to make a major difference for patients with chronic kidney disease (CKD) with and without diabetes when added to angiotensin converting enzyme (ACE) and angiotensin receptor blockers (ARB) classes of medications. Several medications that have been well studied and approved by the FDA in the United States have shown progression of not only CKD but also cardiovascular events and overall mortality. To learn more about these medications, join Dr. Gates Colbert, Assistant Clinical Professor of Medicine at Texas A&M College of Medicine, and Nephrologist and Certified Hypertension Specialist at Kidney and Hypertension Associates of Dallas.
Host: Naomi Fisher, MD
Guest: Florian Rader, MD
Dive into the realm of hypertension management through a chapterized expert interview CME activity on ultrasound renal denervation. In the first chapter, explore the significance of addressing hypertension. Delve into the sympathetic nervous system, ultrasound renal denervation mechanism, and clinical trial data in the second chapter. The third chapter offers dual perspectives on the role of the Hypertension Center, and walks learners through the development process for effective implementation. Gain comprehensive insights from leading experts, Drs. Naomi Fisher and Florian Rader, in this educational series.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Andrew Keaveny, MD
Guest: Don Rockey, MD
Extrahepatic manifestations of decompensated cirrhosis confer significant additional risks for mortality, and a multidisciplinary team of healthcare professionals is involved in the care of these patients. This program will discuss two critical aspects of advanced liver disease: variceal bleeding and hepatorenal syndrome (HRS). These complications pose significant challenges in the management of patients with cirrhosis. Clinically-significant portal hypertension, identified by a hepatic venous pressure gradient >10mmHg, predicts the development of variceal hemorrhage, hepatic encephalopathy, ascites, and HRS, all hallmarks of decompensation and multi-organ failure. Faculty will discuss a common patient presentation to highlight best practices in evidence-based care of patients with variceal bleeding and HRS/acute kidney injury.
Host: Mikhail Kosiborod, MD
Guest: Biff F. Palmer, MD
Delve into refining the management of hyperkalemia in CKD patients and their associated comorbidities, striking a delicate balance that preserves guideline-recommended RAASi therapy. Join Dr. Biff Palmer and Dr. Mikhail Kosiborod as they guide the exploration of novel potassium binders for optimal hyperkalemia management, all while upholding the integrity of established treatment guidelines.
Host: Ashley Baker, MSN, PMHNP
Guest: Chi D. Chu, MD, MAS
The National Health and Nutrition Examination Survey found that kidney disease awareness among patients in the U.S. is very low. And alarmingly, the proportion of awareness has not changed much over the 15-year period of this study. To uncover more of the findings and how to improve CKD awareness, tune into this discussion with Psychiatric Nurse Practitioner Ashley Baker as she takes a deep divewith Dr. Chi D. Chu, Assistant Professor of Medicine in the Division of Nephrology at the University of California San Francisco and coauthor of the article published in the American Journal of Kidney Diseases, titled “CKD Awareness Among US Adults by Future Risk of Kidney Failure.
Guest: Jessica E. Hawley M.D. M.S.
The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, who will also present this topic at the ASCO GU Symposium 2024.
Host: Javed Butler, MD, MBA, MPH
Guest: Chiadi Ndumele, M.D., Ph.D., M.H.S.
For the first time, the American Heart Association (AHA) has identified cardiovascular-kidney-metabolic (CKM) syndrome, which reflects a strong overlap between heart disease, kidney disease, and obesity. The major clinical consequence of CKM syndrome is multi-organ dysfunction with a particularly high incidence and burden of cardiovascular disease (CVD), and the result of this is premature morbidity and mortality. So as a result, recognizing CKM syndrome is the first step in earlier diagnosis and treatment. Dive into this episode with Dr. Javed Butler who’s joined by Dr. Chiadi Ndumele, Associate Professor of Medicine and the Director of Obesity and Cardiometabolic Research at Johns Hopkins University.
Guest: Jai Radhakrishnan, MD
The most widely accepted mechanism for the pathogenesis of immunoglobin A (IgA) nephropathy is referred to as the “four-hit model,” which is a sequence of four events that can occur.1-3 Here to break down each of those four stages is Dr. Jai Radhakrishnan, a nephrologist at Columbia University Medical Center in New York.
References:
- Knoppova B, Reily C, King RG, et al. J Clin Med. 2021;10(19):4501. doi:10.3390/jcm10194501
- Maillard N, Wyatt RJ, Julian BA, et al. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000
- Chang S, Li X-K. Front Med (Lausanne). 2020;7:92. doi:10.3389/fmed.2020.00092
319698 12/23
Guest: Mark Haas, MD
Kidney biopsy is the gold standard for the diagnosis of immunoglobin A (IgA) nephropathy and complement 3 glomerulopathy (C3G),1,2 and the accurate interpretation of kidney biopsy findings is important not only for diagnosis but also guiding clinical management of these conditions. Learn more about what the diagnostic process and findings for IgA nephropathy and C3G look like with Dr Mark Haas, a renal pathologist at Cedars-Sinai Medical Center in Los Angeles.
References:
- Mehdi A, Taliercio JJ. Cleve Clin J Med. 2023;90(6)(suppl 1):e1-e4. doi:10.3949/ccjm.90.e-s1.02
- Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Nephron. 2020;144(6):272-280. doi:10.1159/000507254
319698 12/23
Guest: Richard Lafayette, MD, FACP
Insights into the complement system are critical to our understanding of the pathogenesis of immunoglobin A (IgA) nephropathy.1 That’s why Dr. Richard Lafayette is here to share what we currently know about the complement system and its role in IgA nephropathy. Dr. Lafayette is a nephrologist at Stanford University Medical Center in California.
References:
- Medjeral-Thomas NR, O'Shaughnessy MM. Adv Chronic Kidney Dis. 2020 Mar;27(2):111-119. doi: 10.1053/j.ackd.2019.12.004
319698 12/23
Host: Stefan D. Anker, MD, PhD
Guest: John Cleland, MD
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is a common heart failure comorbidity with a negative impact on patients’ quality of life and mortality. Recent world events may have influenced clinical trial outcomes with IV iron in heart failure, and secondary analysis has become commonplace. Are the findings still clinically relevant, and are we still getting a clinical benefit? Join Drs. Stefan Anker, Piotr Ponikowski, and John Cleland as they differentiate the design of IV iron trials and break down the relevance of key clinical endpoints. Are we still asking the right questions?
Host: George L. Bakris, MD, FAHA, FASN
Guest: David Bushinsky, MD
Guest: Lars Lund, MD
Hyperkalemia is a limiting factor when treating patients with heart failure and CKD on RAASi therapy. It’s especially challenging when these patients are on chronic hemodialysis. Join Drs. George Bakris, David Bushinsky, and Lars Lund as they identify the barriers of optimal treatment in patients on hemodialysis and discuss the real-world evidence using potassium-lowering agents in challenging patient group.
Host: Stefan D. Anker, MD, PhD
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is an independent predictor of decreased functional capacity and reduced survival in our patients with heart failure. Multiple clinical trials have addressed the issue, but we continue to struggle with the clinical implications of the data. Join Drs. Stefan Anker, Robert Mentz, and Piotr Ponikowski as they discuss the evidence from IV iron trials in heart failure, past and present, and what the results mean for your practice and patients.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: John K. Botson, MD, RPh
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Brittany Weber, MD, PhD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Marco Metra, MD
Guest: Gianluigi Savarese, MD
Clinical trials provide evidence to support guideline recommendations. What’s changed with the recommendations for iron deficiency in heart failure? Watch as experts Giuseppe Rosano, MD, Marco Metra, MD, and Gianluigi Savarese, MD discuss the recent updates to the ESC guidelines, including the latest clinical trial evidence, and the expanded use of IV iron in iron deficient heart failure patients.
Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Guest: Maria Luiza Caramori, MD, PhD, MSc
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
Guest: Pam R. Taub, MD, FACC, FASPC
Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.
Host: Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Guest: Patrick Rossignol, MD, PhD
Heart failure and chronic kidney disease can go hand in hand in your patients, and when they do, there are often added comorbidities such as diabetes. If your patients on RAASi therapy develop hyperkalemia, what should you do? Join Drs. Patrick Rossignol and Antoni Bayés-Genís as they consult on a patient with heart failure who has multiple comorbidities and discuss the impact of hyperkalemia in these complex patients.
Host: John Buse, MD, PhD
Guest: David Cherney, MD, PhD
There have been several major advances regarding the management of chronic kidney disease in patients with type 2 diabetes over the last 5 years, leading Dr. David Cherney and a team of authors to publish a narrative review on how to best manage these patients using the latest treatment options like SGLT2 inhibitors and non-steroidal MRAs. Tune in to hear him share key highlights from the review with Dr. John Buse. Dr. Cherney is a Professor of Medicine at the University of Toronto and the Director of the Renal Physiology Laboratory at University Health Network in Canada.
Host: Ellie Kelepouris, MD, FACP, FAHA
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with heart failure and chronic kidney disease (CKD) are challenging to manage. The best approach is a multidisciplinary one, which will help to optimize guideline-directed medical therapy in patients at risk for hyperkalemia. Join Drs. Ellie Kelepouris and Stephen Greene as they discuss how to identify patients at high risk of developing hyperkalemia and the available treatment strategies for these complex patients.
Host: Peter Lin MD, CCFP
Guest: Sri Lekha Tummalapalli, MD, MBA, MAS
Join host, Dr. Peter Lin (Canadian Heart Research Centre, Canada) and Dr. Lekha Tummalapalli (Weill Cornell Medicine, United States) as they discuss the importance of early CKD detection. This episode explores risk factors, screening for CKD, and country-specific factors to take into account when screening for CKD.
This episode is supported by an independent educational grant from AstraZeneca.
Host: Peter Lin MD, CCFP
Guest: Magdalena Madero, MD
In this episode, Dr. Peter Lin (Canadian Heart Research Centre, Canada) and Dr. Magdalena Madero (National Heart Institute Mexico City, Mexico) discuss best practices for CKD evaluation and measurement. This episode focuses on the importance of assessing GFR and albuminuria, identifying the causes of CKD, CKD progression, and when more accurate GFR measures (such as cystatin) should be conducted.
This episode is supported by an independent educational grant from AstraZeneca.
Host: Peter Lin MD, CCFP
Guest: Joel Topf, MD
Join host Dr. Peter Lin (Canadian Heart Research Centre, Canada) in conversation with Dr. Joel Topf (Oakland University, William Beaumont School of Medicine, USA) as they discuss how to combat CKD progression and the role of non-pharmacological vs pharmacological interventions. This episode will explore whether foundational therapies are underused and how to tailor the right treatment for the right patient at the right time.
This episode is supported by an independent educational grant from AstraZeneca.
Host: Peter Lin MD, CCFP
Guest: Ikechi Okpechi
In this episode, Dr. Peter Lin (Canadian Heart Research Centre, Canada) and Ikechi Okpechi (University of Alberta, Canada) discuss the right time to refer patients with CKD to a nephrologist. This episode also addresses rapid CKD progression and the utility of risk prediction equations.
This episode is supported by an independent educational grant from AstraZeneca.
Host: Tessa Laubscher, MBChB, CCFP, FCFP
Guest: George L. Bakris, MD, FAHA, FASN
Guest: Mikhail Kosiborod, MD
Managing chronic kidney disease (CKD) and type 2 diabetes (T2D) with multiple medications has become a challenge, and a multidisciplinary approach is needed to achieve optimal cardiorenal outcomes. Join Drs. George Bakris, Mikhail Kosiborod, and Tessa Laubscher as they discuss initiating consensus-based nonsteroidal MRA therapy in their patients with CKD and T2D.
Host: Piotr Ponikowski, MD, PhD, FESC, FHFA
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
While multiple clinical trials demonstrated a positive impact on patient outcomes with IV iron therapy in patients with HFrEF and iron deficiency, few have addressed the long-term effects of IV iron treatment on morbidity, mortality, and exercise tolerance in these patients. Join Dr. Robert Mentz and Dr. Piotr Ponikowski as they discuss the design of the HEART-FID trial and its potential impact on the clinical applications of long-term treatment with IV iron products in patients with heart failure and iron deficiency.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Patrick Rossignol, MD, PhD
With more effective ways to manage hyperkalemia, is it still a challenge in 2023? Chairperson Ileana Piña, MD, and faculty members cardiologist Javed Butler, MD, and nephrologist Patrick Rossignol, MD, use case-based vignettes to provide expert analysis regarding hyperkalemia in patients with HFrEF who are on RAASi therapy. Tune in for insights on applying clinical trial data to the unique challenges of complex cases and learn how a guideline-based approach, innovative treatments, and emerging data are achieving successful outcomes in patients with heart failure with hyperkalemia.
Host: Jonathan Barratt, PhD
A new class of drugs are looking at the ability to reduce proteinuria and protect the loss of kidney function. So what do clinicians need to know about the treatment landscape for IgA nephropathy? Tune in with Dr. Jonathan Barratt, The Mayer Professor of Renal Medicine at the University of Leicester in the United Kingdom.
Host: Jonathan Barratt, PhD
Genetic studies have shown that changes in the gene for APRIL are associated with an increased risk of developing IgA nephropathy. So what should clinicians know about the ARPIL pathway? Dive in with Dr. Jonathan Barratt, The Mayer Professor of Renal Medicine at the University of Leicester in the United Kingdom.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Pietro A. Canetta, MD
| IgA nephropathy has a few aspects to it that make it challenging to develop medications, particularly, focused medications. So what are the challenges or limitations associated with the therapies? Join Dr. Charles Turck as he discusses this in-depth with Dr. Pietro Canetta, Associate Professor of Medicine at Columbia University Irving Medical Center. Dr. Canetta did not receive compensation for this interview. |
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Pietro A. Canetta, MD
The available treatment options and even the current guidelines for the management of IgA nephropathy (IgAN) come with several limitations. Fortunately, new therapies are on the horizon that can help us address those challenges and slow disease progression in IgAN. Here with Dr. Charles Turck to discuss limitations and advances in the IgAN treatment landscape is Dr. Pietro Canetta, Associate Professor of Medicine at Columbia University Medical Center in New York.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Rajeev Raghavan, MD, M.Ed, FASN
There are several key markers of disease progression in IgA nephropathy (IgAN) that we should be aware of, and the biochemical pathways involving endothelin-1 (ET-1) and angiotensin II (Ang II) play an important role in driving that progression. Joining Dr. Charles Turck to shed light on these two pathways and how our knowledge of ET-1 and Ang II may impact the treatment landscape is Dr. Rajeev Raghavan, Program Director for HCA Kingwood Internal Medicine in Texas.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gates B. Colbert, MD, FASN
Preserving kidney function in our patients with IgA nephropathy (IgAN) is absolutely critical as it reduces the burden of disease our patients face, but there’s still room for improvement when it comes to proactively preventing kidney damage. So how can we optimize our approach to reduce that burden and preserve kidney function? Joining Dr. Charles Turck to share essential strategies is Dr. Gates Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gates B. Colbert, MD, FASN
Preserving kidney function in our patients with IgA nephropathy (IgAN) is absolutely critical as it reduces the burden of disease our patients face, but there’s still room for improvement when it comes to proactively preventing kidney damage. So how can we optimize our approach to reduce that burden and preserve kidney function? Joining Dr. Charles Turck to share essential strategies is Dr. Gates Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.
Host: Mario Cozzolino, MD, PhD
Guest: Jan T. Kielstein, MD, FASN, FERA
A high percentage of patients with chronic kidney disease have low levels of vitamin D leading to secondary hyperparathyroidism (SHPT), which plays a critical role in the development of chronic kidney disease-mineral and bone disorder (CKD-MBD). Our experts, Dr. Mario Cozzolino and Dr. Jan Kielstein, discuss the complexity of the condition, early diagnosis, treatment goals, and emerging therapies. Tune in to be sure you’re using all the tools at your disposal to improve your patients’ quality of life.
Host: Mario Cozzolino, MD, PhD
Guest: Jan T. Kielstein, MD, FASN, FERA
A high percentage of patients with chronic kidney disease have low levels of vitamin D leading to secondary hyperparathyroidism (SHPT), which plays a critical role in the development of chronic kidney disease-mineral and bone disorder (CKD-MBD). Our experts, Dr. Mario Cozzolino and Dr. Jan Kielstein, discuss the complexity of the condition, early diagnosis, treatment goals, and emerging therapies. Tune in to be sure you’re using all the tools at your disposal to improve your patients’ quality of life.
Host: Mario Cozzolino, MD, PhD
Guest: Jan T. Kielstein, MD, FASN, FERA
A high percentage of patients with chronic kidney disease have low levels of vitamin D leading to secondary hyperparathyroidism (SHPT), which plays a critical role in the development of chronic kidney disease-mineral and bone disorder (CKD-MBD). Our experts, Dr. Mario Cozzolino and Dr. Jan Kielstein, discuss the complexity of the condition, early diagnosis, treatment goals, and emerging therapies. Tune in to be sure you’re using all the tools at your disposal to improve your patients’ quality of life.
Host: Gates B. Colbert, MD, FASN
Although immunosuppressive therapy has been the backbone of IgA nephropathy (IgAN) treatment, this type of approach comes with several challenges. Here to share how non-immunosuppressive treatments could help revolutionize the IgAN treatment landscape is Dr. Gates B. Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.
Host: David Jayne, MD
Guest: Annette Bruchfeld, MD, PhD
ANCA-associated vasculitis (AAV) may lead to long-term organ damage and has a significant mortality risk for patients. While glucocorticoids are effective, they are associated with adverse events and impaired quality of life. Join our experts as they tackle these unmet needs in the context of the guidelines and current treatments and then dive deeper with an exploration of the potential role of complement receptor inhibition, which may be the answer to improving vasculitis.
Host: David Jayne, MD
Guest: Annette Bruchfeld, MD, PhD
ANCA-associated vasculitis (AAV) may lead to long-term organ damage and has a significant mortality risk for patients. While glucocorticoids are effective, they are associated with adverse events and impaired quality of life. Join our experts as they tackle these unmet needs in the context of the guidelines and current treatments and then dive deeper with an exploration of the potential role of complement receptor inhibition, which may be the answer to improving vasculitis.
Host: Smeeta Sinha, PhD
Guest: Sagar Nigwekar, MD
High-quality evidence for the management of calciphylaxis is lacking due to the rare nature of the disease and its poorly understood pathogenesis. Our experts, Drs. Smeeta Sinha and Sagar Nigwekar, discuss the complexity of the condition, its diagnosis, treatment goals, and emerging therapies. Tune in to be sure you’re using all the tools at your disposal to improve your patients’ quality of life.
Host: Smeeta Sinha, PhD
Guest: Sagar Nigwekar, MD
High-quality evidence for the management of calciphylaxis is lacking due to the rare nature of the disease and its poorly understood pathogenesis. Our experts, Drs. Smeeta Sinha and Sagar Nigwekar, discuss the complexity of the condition, its diagnosis, treatment goals, and emerging therapies. Tune in to be sure you’re using all the tools at your disposal to improve your patients’ quality of life.
Host: Javed Butler, MD, MBA, MPH
Guest: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, there is a propensity to down-titrate or discontinue guideline-directed medical therapy in the presence of hyperkalemia, even though it is well known that suboptimal use of these therapies leads to poorer outcomes for our patients with heart failure and chronic kidney disease. Join Drs. Javed Butler, Ileana Piña, and Patrick Rossignol as they take a multidisciplinary approach to a patient case and discuss dosing and other treatment decisions.
Host: Vladimir Tesar, MD
Guest: Michael Walsh, MD
In this episode, host Dr. Vladimir Tesar (General University Hospital, Prague) and Dr. Micheal Walsh (McMaster University, Canada) explore the benefits of plasma exchange for patients with ANCA-associated vasculitis. This episode discusses how to identify patients who may benefit from plasma exchange and the role of plasma exchange in patients with double-positive ANCA and anti-GBM. The utility of rituximab in those also treated with plasma exchange will be addressed.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Vladimir Tesar, MD
Guest: David Jayne, MD
Host Dr. Vladimir Tesar (General University Hospital, Prague) and Dr. David Jayne (Addenbrooke's Hospital, United Kingdom) discuss the roles of various agents in the induction and maintenance treatment of ANCA- associated vasculitis. They will explore the use of rituximab and complement inhibition in treating ANCA-associated vasculitis. This episode will address the gaps in knowledge and ongoing research in the field of ANCA-associated vasculitis.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Vladimir Tesar, MD
Guest: Duvuru Geetha, MD
Join host, Dr. Vladimir Tesar (General University Hospital, Prague), in conversation with Dr. Duvuru Geetha (Johns Hopkins University School of Medicine, United States) as they discuss the main causes of delays in diagnosis of ANCA-associated vasculitis and the different ways to increase awareness of the disease. This episode will also discuss the role of kidney biopsy in the optimal management and monitoring of these patients.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Frederic Rahbari-Oskoui, MD, MSc
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Frederic Rahbari-Oskoui, MD, MSc
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Frederic Rahbari-Oskoui, MD, MSc
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Jürgen Floege, MD
Guest: Jonathan Barratt, PhD
Guest: David Jayne, MD
Patients with chronic kidney disease often have a multitude of comorbidities which may present challenges in diagnosis, treatment, and management. In addition, the limitations of currently available treatments may reduce the opportunity for effective improvements in their quality of life. But clinical trial data are emerging, and our understanding about the underlying mechanisms of glomerulonephritis and sclerosis is growing. Find out how these advances could lead to improved outcomes in patients with IgAN, FSGS, and AAV.
Host: Fouad T. Chebib, MD
Guest: Pranav S. Garimella, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Martin Pollak, MD
Guest: Susanne Nicholas, MD, MPH, PhD
End-stage kidney disease (ESKD) is at least 3x higher among African Americans compared to Americans of European descent. Carriers of APOL1 variants with chronic kidney disease (CKD) are associated with more rapid disease progression and an increased risk of kidney failure. Join Drs. Martin Pollak and Susanne Nicholas as they discuss the epidemiology and possible mechanisms of APOL1 kidney disease, as well as recent clinical evidence for therapies in development that can potentially prevent rapid disease progression.
Host: Javed Butler, MD, MBA, MPH
Guest: Stefan D. Anker, MD, PhD
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Symptoms from iron deficiency can greatly affect the overall quality of life of our patients with heart failure. Recent clinical evidence from the IRONMAN trial explores the use of IV iron replacement in patients with chronic heart failure. Join Drs. Javed Butler, Stefan Anker, Piotr Ponikowski, and Robert Mentz as they discuss the clinical trial design and outcomes from IRONMAN compared to the current body of evidence for managing iron deficiency in this setting.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Michael Donovan, PhD, MD
Diabetic kidney disease (DKD) can be burdensome for patients—especially if it progresses. How can we find out if our patients are at risk of progression? To answer that question, Dr. Charles Turck is joined by Dr. Michael Donovan to discuss a prognostic tool for type 2 diabetes patients with early-stage (stage 1-3b) chronic kidney disease.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Michael Donovan, PhD, MD
Diabetic kidney disease (DKD) can be burdensome for patients—especially if it progresses. How can we find out if our patients are at risk of progression? To answer that question, Dr. Charles Turck is joined by Dr. Michael Donovan to discuss a prognostic tool for type 2 diabetes patients with early-stage (stage 1-3b) chronic kidney disease.
Host: Marlies Ostermann, MD
Guest: Sandra L. Kane-Gill, PharmD, MS, FCCM, FCCP
Join host, Dr. Marlies Ostermann (Guy's and St Thomas' Hospital, United Kingdom), in conversation with Dr. Sandra Kane-Gill (University of Pittsburgh School of Pharmacy, United States) as they discuss the importance of drug stewardship when treating critically ill patients. This episode will examine various terms such as drug-induced acute kidney injury, drug-associated acute kidney injury, and nephrotoxicity. Dr. Kane-Gill will also discuss how multiorgan support may influence drug dosing and aspects of nutrition and micronutrient supplementation for patients with AKI.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Kamyar Kalantar‐Zadeh, MD
Guest: Pieter Martens, MD, PhD
Patients with heart failure are at increased risk for iron deficiency which leads to poor outcomes and quality of life. Several intravenous iron formulations are available to clinicians, yet iron deficiency remains undertreated. Join Dr. Giuseppe Rosano, Dr. Pieter Martens, and Dr. Kamyar Kalantar-Zadeh as they discuss differing iron formulations and the current body of evidence for managing iron deficiency in patients with heart failure.
Host: Marlies Ostermann, MD
Guest: Javier Neyra, MD, MSCS
Join host, Dr. Marlies Ostermann (Guy's and St Thomas' Hospital, United Kingdom), in conversation with Dr. Javier Neyra (University of Alabama in Birmingham, United States) as they explore the role of kidney replacement therapy in managing fluid overload. They will discuss optimal monitoring and how best to remove fluid safely and effectively, including the evaluation of patients’ response to fluid removal prescription. This episode will also address the ongoing gaps in knowledge in the field.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Marlies Ostermann, MD
Guest: Rinaldo Bellomo, MBBS, MD, FRACP
In this episode, KDIGO Conversations in Nephrology host, Dr. Marlies Ostermann (Guy's and St Thomas' Hospital, United Kingdom), and Dr. Rinaldo Bellomo (University of Melbourne, Australia) will discuss the importance of hemodynamic stabilization in protecting kidney function for patients on kidney replacement therapy. This episode will also discuss the different strategies and therapies available for maintaining such stability. Urgent questions for future research will also be addressed.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Jennifer Caudle, DO
Guest: Joseph Aloi, MD
The rate of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) continues to rise. What can we do to slow this progression of CKD? Dr. Joseph Aloi from the Wake Forest School of Medicine explores this growing epidemic and discusses how a new tool may aid in early risk assessment of early stage 1-3b CKD.
Host: Theodora A. Potretzke, MD
Guest: Fouad T. Chebib, MD
This Expert Exchange webcast is designed to help improve clinicians’ understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency in patients with heart failure remains underdiagnosed, undertreated, and commonly overlooked in non-anemic patients and has a significant impact on patient outcomes and quality of life. Join Dr. Robert Mentz and Dr. Peter van der Meer as they discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.
Guest: Neera Dahl, MD, PhD
Guest: Craig E. Gordon, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Charles P. Vega, MD
Guest: Rajeev Raghavan, MD, M.Ed, FASN
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Javier Morales, MD, FACP, FACE
Out of the 32 million patients with diabetes in the United States, 40 percent also have chronic kidney disease. But what’s even more alarming is that only 10 percent of these patients know they have chronic kidney disease. So what strategies can we use to address the unmet needs and barriers faced when managing patients with chronic kidney disease and type 2 diabetes? Joining Dr. Charles Turck to answer this and other key questions is Dr. Javier Morales, Associate Clinical Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell on Long Island.
Guest: Mikhail Kosiborod, MD
Patients with diabetes-related chronic kidney disease (CKD) are at high risk for a number of adverse events over a relatively short period of time. So what do we have in terms of efficacious therapies that can help make a positive impact in that regard? Here to share what we need to know about non-steroidal mineralocorticoid receptor antagonists (MRAs) for the treatment of diabetes-related CKD is Dr. Mikhail Kosiborod, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute.
Guest: Gates B. Colbert, MD, FASN
Approximately 34 million patients live with diabetes in the United States, and up to 40 percent of those patients also have chronic kidney disease (CKD). That’s why it’s so important to know how to identify and prevent CKD progression in patients with diabetes, and here to share key strategies is Dr. Gates Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.
Host: Javed Butler, MD, MBA, MPH
Guest: Tariq Shafi, MD
Although population-level differences between estimated glomerular filtration rate (eGFR) and measured glomerular filtration rate are well-known, the individual-level differences are not. So what clinical implication can this have for our patients? Learn about these fresh findings with Dr. Javed Butler and Dr. Tariq Shafi, the John D. Bower Director of the Division of Nephrology and Professor of Medicine at the University of Mississippi Medical Center. Together, they discuss a recent study from the Annals of Internal Medicine that explored this topic.
Host: Marco Metra, MD
Guest: Piotr Ponikowski, MD, PHD, FESC, FHFA
Iron deficiency, independent of anemia status, is common in heart failure and is associated with increased risk for heart failure hospitalization and cardiovascular mortality, reduced functional status, and poor exercise performance. This impact may be magnified in patients with ischemic etiology. Join Dr. Marco Metra and Dr. Piotr Ponikowski as they discuss the clinical relevance of ischemic etiology in the management and outcomes of patients with heart failure and iron deficiency.
Host: Mikhail Kosiborod, MD
Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.
Host: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Javier Morales, MD, FACP, FACE
Guest: Angela Yee-Moon Wang, MD, FACP, FACE
Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) and is associated with mortality and morbidity worldwide. Recent data on the use of nonsteroidal MRAs were presented at the European Society of Cardiology and other major meetings and were simultaneously published in major journals. Join our experts to explore these data and find out how you can better prevent the deterioration of renal function and improve cardiovascular outcomes in your patients across the spectrum of renal decline.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Paul Kwo, MD
The treatment landscapes for alcoholic hepatitis and acute kidney injury in cirrhosis are evolving. So how are we now defining acute kidney injury with cirrhosis, and how should we treat these two conditions based on the latest therapeutic updates? To find out, Dr. Peter Buch speaks with Dr. Paul Kwo, Professor of Medicine and Director of Hepatology at Stanford University.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Marco Metra, MD
Guest: Adrian F. Hernandez, MD, MHS
Since the 2017 AHA/ACC/HFSA guidelines, considerable research has been conducted in the care of patients with heart failure, including the impact of iron deficiency. The new 2022 guidelines have considerable updates based on the totality of current evidence. Join Dr. Adrian Hernandez and Dr. Marco Metra as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.
Host: Mikhail Kosiborod, MD
Guest: Michael Böhm, MD, FESC
The 2022 updates to the ACC/AHA guidelines for heart failure are the first since 2017. In the interim, considerable research has been conducted on the impact of optimal RAASi therapy and the management of hyperkalemia in patients with heart failure. Join Dr. Mikhail Kosiborod and Dr. Michael Böhm as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Anjay Rastogi, MD, PhD
Defined as high potassium levels in the blood, hyperkalemia can be a life-threatening condition.1 Hyperkalemia is often associated with chronic kidney disease and can be silent or present itself with non-specific symptoms.1,2 However, there are challenges in managing hyperkalemia as a recurrent event.1,3 To help address these challenges, Dr Charles Turck discusses with Dr Anjay Rastogi, nephrologist and head of the CORE Kidney Program at UCLA, the burden of hyperkalemia and how potassium binders can help manage it.3,4 ©2022 AstraZeneca. All rights reserved. US-57356 Last Updated 2/22
Guest: Samira Farouk, MD
The #NephMadness bracket will follow along with this year's National Kidney Foundation Spring Clinical Meeting, and Dr. Samira Farouk from the Icahn School of Medicine at Mount Sinai shares what you can do to get involved and what sessions she's looking forward to attending at this year's meeting.
Guest: Samira Farouk, MD
What can we expect to see at the upcoming Nation Kidney Foundation Spring Clinical Meeting? Dr. Samira Farouk from the Icahn School of Medicine at Mount Sinai shares what sessions she's looking forward to seeing on dialysis access, care coordination, and equitable patient care.
Guest: Vandana Niyyar, MD
What can we expect to see at the 2022 National Kidney Foundation Spring Clinical Meeting? Dr. Vandana Niyyar shares what sessions she plans on attending at this year's meeting, and what she's looking forward to seeing.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eugene E. Wright, Jr., MD
Guest: Marina Basina, MD
What are some ways we can detect chronic kidney disease in patients with type 2 diabetes early? Joining Dr. Charles Turck to share collaborative strategies for early detection are Dr. Marina Basina from Stanford University Medical Center and Dr. Eugene Wright from the Charlotte Area Health Education Center.
Host: Mikhail Kosiborod, MD
Guest: Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
RAASi therapy is a critical component of heart failure management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. This is especially evident in our patients with chronic kidney disease. So how can we simultaneously maintain optimal therapy and manage hyperkalemia? Join Dr. Mikhail Kosiborod and Dr. Austin Stack as they discuss a patient case and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: Jennifer Caudle, DO
Guest: David S. Batt, MD
Many factors can lead to diagnostic delays when it comes to systemic lupus erythematosus (SLE), such as the wide range of clinical manifestations and the variable age of onset. So given those factors, how can we get better at recognizing SLE early on to help close the diagnostic gap? And then once we do diagnose patients, what strategies can we use to tighten the therapeutic window? Joining Dr. Jennifer Caudle to answer those and other key questions regarding early intervention strategies for SLE is Dr. David Batt.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: Eugene E. Wright, Jr., MD
Guest: Jolanta Małyszko, MD, PhD
Guest: María José Soler, MD, PhD
Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.
Host: Jacob Sands, MD
Guest: Daniel G. Arkfeld, MD
The focus of lupus treatment has evolved from controlling symptoms to taking a treat-to-target approach to help patients feel more comfortable and to prevent organ damage. So what role do biologics play in all of this? Find out with Dr. Jacob Sands as he speaks with Dr. Daniel Arkfeld, who shares key insights on this approach to treating lupus.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gates B. Colbert, MD, FASN
Guest: Robin Dore, MD
When managing patients with lupus nephritis, it’s imperative that rheumatologists and nephrologists work together to coordinate care. Unfortunately, several challenges can keep us from putting care coordination strategies into practice, so how can we overcome those challenges and incorporate shared decision-making into our clinical approach to lupus nephritis? Joining Dr. Charles Turck to share their perspectives are rheumatologist Dr. Robin Dore and nephrologist Dr. Gates Colbert.
Host: Javed Butler, MD, MBA, MPH
Guest: Stefan D. Anker, MD, PhD
The DIAMOND trial recently released topline results, adding to the growing clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. So what do the data mean for our patients? Join Dr. Stefan Anker and Dr. Javed Butler as they discuss the value of these results and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: Peter Rossing, DMSc, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Matthew R. Weir, MD
Achieving optimal outcomes in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remains a challenge, and treating physicians need to embrace multidisciplinary components when managing progression to CKD.
In this discussion, Drs. Gerasimos Filippatos, Peter Rossing, and Matthew Weir review the unmet needs of patients with CKD and T2D. They also explore the role of mineralocorticoid receptor antagonists (MRAs) in the treatment spectrum and review recent findings from clinical trials. Tune in to ensure you’re doing all you can for each of your patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Murray Epstein, MD
Guest: Gates B. Colbert, MD, FASN
Determining the optimal strategies for treating patients with chronic kidney disease (CKD) can be challenging. After decades of waiting, exciting and rapid progress in renin-angiotensin-aldosterone system (RAAS) inhibition is being made, but these therapies can lead to hyperkalemia. The trick is to sustain optimal therapy in the patient without interruption or reduction. Are you familiar with novel potassium binders and recent changes in guideline-directed medical therapy surrounding their use? Tune in because these resources are offering new therapeutic opportunities for your patients with CKD.
Join Drs. Murray Epstein and Gates Colbert to ensure you’re up to date on the latest treatment options for your patients with CKD.
Host: Peter van der Meer, MD, PhD
Guest: Pieter Martens, MD, PhD
Iron deficiency (ID), independent of anemia status, is common in heart failure with reduced ejection fraction (HFrEF). In normal cardiac physiology, contractility increases disproportionally to heart rate; however, in HFrEF and concomitant ID, this response is impaired. Additionally, HFrEF patients with ID who receive cardiac resynchronization therapy (CRT) exhibit diminished cardiac reverse remodeling after CRT implant.
In this discussion, Drs. Martens and van der Meer discuss how physicians can work to improve reverse cardiac remodeling, the force-frequency relationship, and quality of life in patients with HFrEF and ID receiving CRT.
Guest: George L. Bakris, MD
From diagnostic criteria to risk stratification, what do we need to know about recognizing early-stage diabetic kidney disease? Dr. George Bakris from the University of Chicago Medicine discusses detection strategies for diabetic kidney disease.
Host: George L. Bakris, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Hyperkalemia is common in chronic heart failure and is associated with an increased risk of hospitalization and death. The incidence is further elevated in those with chronic kidney disease, and the presence of hyperkalemia can often lead to clinical delay and suboptimal dosing of RAAS inhibitors in these patients.
Join the discussion as Drs. George Bakris and Giuseppe Rosano examine the management of hyperkalemia in patients with HF and provide individualized approaches for optimizing RAASi therapy. Collaboration between nephrologists and cardiologists is key, and these experts make sure to stress the strong connection between the heart and kidneys when managing these patients.
Host: Jennifer Caudle, DO
Guest: Jennifer B. Green, MD
What are some ways we can close the gaps in care for patients with diabetic kidney disease? Dr. Jennifer Caudle is joined by Dr. Jennifer Green from the Duke University School of Medicine to explore management challenges and share strategies to optimize care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Marco Metra, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
In the management of patients with heart failure, foundational therapy is critical to improving patient outcomes. Are you up to date on the latest recommendations concerning MRAs, ACEI/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors? Recent updates to the ESC/HFA guidelines, heart failure clinical trials, and the COVID-19 pandemic have impacted the way we manage our patients, so tune in to keep up with the latest developments.
Our experts, Drs. Ileana Piña, Javed Butler, Marco Metra, and Giuseppe Rosano, discuss the ESC/HFA guideline updates and how these changes impact the clinical considerations for managing recurrent hyperkalemia and the recommended foundational therapy for patients with heart failure.
Host: Mikhail Kosiborod, MD
Guest: Javed Butler, MD, MBA, MPH
Guest: Matthew R. Weir, MD
Renin-angiotensin-aldosterone system inhibition (RAASi) is the foundation of guideline-directed medical therapy (GDMT) for heart failure patients. However, due to practice gaps, a significant proportion of the population requiring its use do not experience the benefits of RAASi therapy, which is especially true for patients with comorbid conditions. Hyperkalemia is a common adverse effect of RAASi therapy that needs to be anticipated and mediated so that the optimal dosing of necessary medications can occur. Maximizing GDMT in the face of hyperkalemia remains a key clinical challenge that, if not handled properly, can result in increased morbidity and mortality.
In this activity, Drs. Javed Butler, Mikhail Kosiborod, and Matthew Weir review a patient case and discuss different treatment approaches to optimize GDMT while managing hyperkalemia. Tune in to make sure you’re doing all you can to improve outcomes for your patients with heart failure and comorbid conditions.
Guest: Maureen Brogan, MD
The COVID-19 pandemic has impacted care across all specialties, and the 2021 American Society of Nephrology (ASN) Annual Meeting offered a platform for nephrologists to share their experiences. Tune in to hear how Dr. Maureen Brogan adapted her practice to overcome supply and staffing shortages.
Guest: Maureen Brogan, MD
By focusing on patient-driven kidney care, innovation can emerge. Here to review this topic that was featured at the 2021 American Society of Nephrology (ASN) Annual Meeting is Dr. Maureen Brogan, an Associate Professor of Medicine at Albert Einstein College of Medicine and the Clinical Director in the Division of Nephrology at Montefiore Medical Center.
Guest: Maureen Brogan, MD
From emerging treatment options to finding new ways to combat healthcare disparities, a lot was covered at the 2021 American Society of Nephrology (ASN) Annual Meeting. And here to talk about some of the latest updates is Dr. Maureen Brogan, an Associate Professor of Medicine at Albert Einstein College of Medicine and the Clinical Director in the Division of Nephrology at Montefiore Medical Center.
Host: Javed Butler, MD, MBA, MPH
Guest: Piotr Ponikowski, MD, PHD, FESC, FHFA
In this video, Drs. Javed Butler and Piotr Ponikowski discuss the clinical significance of iron deficiency in patients suffering from heart failure with reduced ejection fraction. They also take a close look at the key updates to the 2021 ESC/HFA guidelines. Tune in to stay up to date with the latest recommendations.
Guest: John Friedewald, MD
The 2021 American Society of Nephrology Annual Meeting covered everything from inequities in organ allocation to policy updates. Here to share those and other key takeaways from the conference is Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine.
Guest: John Friedewald, MD
Could novel technologies like noninvasive biomarkers help us achieve the goal of “one kidney for life”? Find out with Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine, as he shares the latest developments that can help monitor patients with kidney transplants.
Host: Gregg C. Fonarow, MD
Guest: Andrew J. S. Coats, MD
Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.
In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.
Host: Keith C. Ferdinand, MD
Guest: Marco Metra, MD
There is a substantial gap between the guideline recommendations for treatment and the real-world prescribing patterns of RAASi therapy. This disconnect results in worse cardiorenal outcomes and higher mortality in patients receiving suboptimal dosing. This is particularly true in patients with CKD who develop hyperkalemia, which constitutes the major barrier to optimal therapy.
In this activity, Drs. Ferdinand and Metra discuss how best to manage comorbidities, optimize RAASi therapy, and improve the long-term care for our patients with heart failure.
Guest: John Friedewald, MD
Kidney Week 2021 tackled everything from kidney transplants to systemic inequities. Here to share his insight on the latest updates is Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine.
Guest: John Friedewald, MD
What did the first day of the American Society of Nephrology’s Kidney Week 2021 showcase? From COVID-19 to developments in kidney disease, Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine, shares highlights from Day 1.
Host: Mikhail Kosiborod, MD
Guest: Ewa A. Jankowska, MD, PhD, FESC
Guest: Phil McEwan, PhD
Assessing iron deficiency is a crucial aspect of heart failure (HF) that warrants close clinical consideration, especially because it remains underdiagnosed and undertreated.
In this expert panel discussion, we examine data from AFFIRM-HF supporting the importance of correcting iron deficiency in patients with HF. Find out how treating iron deficiency can change the natural history of heart disease, lead to cost savings, and improve patients’ lives.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Guest: Steven Fishbane, MD
Guest: Shayan Shirazian, MD
Host: Jennifer Caudle, DO
At least 25% of patients with chronic kidney disease (CKD), and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This case-based program will apply the foundational information presented in the first program of this 2-part series to real-world patients.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Rapid initiation and up-titration of guideline-directed medical therapy (GDMT) is critical to achieve optimal patient outcomes in heart failure. This is particularly important in patients with multiple comorbidities and in pivotal situations to avoid stopping or lowering the dose of any of the four critical medicines that these patients must receive.
Drs. Javed Butler, Ileana Piña, and Giuseppe Rosano will recap the data and the views that were presented at a symposium held in conjunction with the Heart Failure Society of America’s 2021 annual scientific meeting.
Host: Charles P. Vega, MD
Guest: Robert O. Roswell, MD, FACC, FACP
Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.
Host: Roberto Pecoits-Filho, MD, PHD, FACP, FASN, PHD
Guest: Charles Herzog, MD, FACC, FAHA
Drs. Pecoits-Filho and Herzog explore the challenges that occur when managing dyskalemia. Their conversation addresses consequences of hyperkalemia and hypokalemia. They also discuss how both hospitalized patients and outpatients are affected by acute hyperkalemia.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Roberto Pecoits-Filho, MD, PHD, FACP, FASN, PHD
Guest: Patrick Rossignol, MD, PhD
Covered in this conversation is Dr. Rossignol’s personal approach to RASi optimization and monitoring of creatinine and potassium. Also discussed are recommendations for clinicians based on the latest guidelines.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Roberto Pecoits-Filho, MD, PHD, FACP, FASN, PHD
Guest: Catherine Clase, MB BChir, BA, MSc, FRCPC
Dr. Clase explains the main evidence-based reasons to use RASi as a cardio-protective therapy and the practical challenges involved. Drs. Pecoits-Filho and Clase also discuss the multiple strategies that can be used for potassium management.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Charles P. Vega, MD
Guest: Lionel Phillips, MBA
Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Charles P. Vega, MD
Guest: Candice Taylor Lucas, MD, MPH, FAAP
What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?
Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.
Guest: Steven Fishbane, MD
Guest: Shayan Shirazian, MD
Host: Jennifer Caudle, DO
At least 25% of patients with chronic kidney disease (CKD) and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life, and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This first program will review the epidemiology, consequences, evaluation, pathophysiology and available and emerging treatments for CKD-aP; a second case-based program will apply the information to real-world patients.
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have not only disrupted the regular care of patients with heart failure, but also clinical trials and their participation rates.
These studies are critical for determining the safety and efficacy of new drugs and innovative treatments. When the pandemic started, some clinical trials shut down permanently while others are finally, albeit slowly, resuming. This has created a delay in the research pipeline that may hinder how quickly new heart failure medications come to market in the next few years.
Join us as our experts—Drs. Deepak Bhatt, Javed Butler, and Giuseppe Rosano—discuss the impact of COVID-19 on patient care and the implications for clinical trial data moving forward.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joseph William Ray, MD
Fabry disease is a progressive, genetic disorder that can cause multisystemic damage and reduce life expectancy when left undiagnosed and unmanaged, making the timely and appropriate management of Fabry disease essential. Recent clinical outcome data and real-world evidence led to the approval of Fabrazyme, a treatment option for Fabry disease. Joining Dr. Charles Turck to share that data is Dr. Joseph William Ray, an Associate Professor of Pediatrics and Director of Medical Genetics at the University of Texas Medical Branch.
For more information, please visit www.fabrazyme.com/hcp.
MAT-US-2107750-v1.0-08/2021
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency is an extremely common comorbidity for 50% to 70% of our patients with heart failure in both the acute and chronic settings. It’s associated with poor exercise capacity, poor quality of life, and increased morbidity and mortality. In hospitalized patients with acute heart failure, iron deficiency is often present independent of anemia.
With that in mind, join Drs. Robert Mentz and Peter van der Meer as they discuss the impact of iron deficiency on patients with heart failure. Find out why it’s time to shift our perception of iron deficiency from a marker of disease outcome to a treatment target.
Host: George L. Bakris, MD
Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU
Guest: Bertram Pitt, MD
Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their progression to ESRD and improve their cardiovascular outcomes. Drs. Rajiv Agarwal, George Bakris, and Bertram Pitt review data from the FIGARO-DKD trial and the FIDELITY Analysis to explore the evolving role of mineralocorticoid receptor antagonists (MRAs) as part of the overall treatment plan for patients with diabetes and CKD. Don’t miss this potentially practice-changing session!
Guest: Arlene B. Chapman, MD
Guest: Michel Chonchol, MD
This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Michelle Y. Owens, MD
OB-GYN clinicians can improve how they communicate with their patients about hemolytic disease of the fetus and newborn or HDFN. Strategies include encouraging patients to talk about their feelings when learning about this condition and communicating with them in terms that are not overly complex. In this program, Drs. Lee Shulman and Michelle Owens discuss how to break things down for the patient in front of you and explain how to use a read-back approach. This tactic ensures that your patient has absorbed what was discussed and also allows you to identify gaps in her understanding that can be addressed with further counseling.
Host: Jay Raman, MD, FACS
Guest: Oguz Akin, MD
Guest: Robert J. Motzer, MD
Guest: Elizabeth Plimack, MD, MS
Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
It is well understood that RAASi therapy is critical in the management of patients with heart failure. However, hyperkalemia is common in these patients, and its presence often leads to suboptimal RAASi dosing, which in turn results in poorer patient outcomes. Join Drs. Javed Butler and Giuseppe Rosano as they look at a case presentation and discuss the hows and whys of optimal RAASi dosing in patients with heart failure and recurrent hyperkalemia.
Host: George L. Bakris, MD
Guest: Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
Guest: Robert Toto, MD
When treating patients with heart failure and chronic kidney disease, RAASi therapy should be continued if at all possible. One thing to keep in mind is that an elevation in serum creatinine does not always represent acute kidney injury. In this activity, Drs. George Bakris, Biykem Bozkurt, and Robert Toto examine a case study and discuss transient changes in serum creatinine with hyperkalemia. Join us to find out how and why you should avoid RAAS blockade interruption in these patients.
Guest: Michel Chonchol, MD
Guest: Frederic Rahbari-Oskoui, MD, MS
This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD.
Guest: Matthew B. Lanktree, MD, PhD
Guest: Neera Dahl, MD, PhD
This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.
Host: Jacob Sands, MD
Guest: Brad McGregor, MD
Non-clear cell renal cell carcinoma is one of the rare diseases with limited treatment data, creating many challenges for oncologists. But could recent updates radically change the landscape? To find out, Dr. Jacob Sands speaks with Dr. Brad McGregor, the Clinical Director for the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, to discuss developments in the management of non-clear cell renal cell carcinoma.
Guest: Arlene B. Chapman, MD
Guest: Matthew B. Lanktree, MD, PhD
This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.
Guest: Rana McKay, MD
Host: Paul P. Doghramji, MD, FAAFP
Dr. Rana Mckay, a Medical Oncologist and Assistant Professor of Medicine at the University of California San Diego, explores the role of surveillance and frontline local therapy for patients with advanced renal cell carcinoma
Guest: Wenxin Xu, MD
Host: Paul P. Doghramji, MD, FAAFP
Dr. Paul Doghramji joins Dr. Wenxin Xu, a physician at the Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School, to take a look at some of the key factors guiding treatment decisions and disease management for patients with advanced renal cell carcinoma.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise, Jr., MD
Guest: Christopher Robinson, MD
Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical.
Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.
Host: George L. Bakris, MD
Guest: Biff F. Palmer, MD
In this case-based activity, Drs. George Bakris and Biff Palmer discuss the benefits of RAAS inhibitors in the patient diagnosed with diabetes, hypertension, and chronic kidney disease. They review the importance of titrating RAAS inhibitors to the highest tolerated recommended dose and identify obstacles to optimizing the dosing of these therapies in patients with comorbidities. They also discuss the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy.
Host: Peter McCullough, MD
Host: Rachel Pessah-Pollack, MD
Coexistence of cardio-renal-metabolic (CRM) disorders may increase the risk of mortality in patients. Here Drs. Peter McCullough and Rachel Pessah-Pollack discuss the effects of coexisting CRM disorders on cardiovascular mortality and overall life expectancy, as well as how a collaborative care approach could improve patient outcomes.
This is part 3 of a 3-part podcast series. Please listen to podcasts 1 and 2 before listening to this podcast.
Copyright © 2021 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
Host: Peter McCullough, MD
Host: Rachel Pessah-Pollack, MD
The presence of multiple disorders of the cardio-renal-metabolic (CRM) systems can increase the risk of morbidity in patients. In this video, Drs. Peter McCullough and Rachel Pessah-Pollack will discuss the coexistence of CRM disorders, their impact on the continuum of disease risk, and the collaborative care approach to managing these interconnected disorders.
This is part 2 of a 3-part podcast series. Please listen to podcast 1 before listening to this podcast.
Copyright © 2021 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
SC-US-69643-D (06/2021)
Host: Ravindra L. Mehta, MD
Guest: Theresa Mottes, APRN-NP, CPNP-AC, CDN
Drs. Mehta and Mottes’ conversation covers what key components are needed when starting a quality improvement program (QI) for acute dialysis and why they are needed. They also discuss how to get leverage to implement a QI program and the keys to a successful CRRT quality program.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Ravindra L. Mehta, MD
Guest: Marlies Ostermann, MD
In this episode, Dr. Ravi Mehta and Dr. Marlies Ostermann discuss the controversy around defining the optimal timing for starting dialysis in critically ill patients. Dr. Osterman highlights the most relevant parameters that influence when to offer, start, and stop dialysis and gives a comprehensive review of the recent trails on timing of dialysis. And finally, both presenters address the challenges managing patients during the COVID-19 pandemic.
Host: Ravindra L. Mehta, MD
Guest: Ashita Tolwani, MD
Dr. Mehta and Dr. Tolwani discuss best practices on anticoagulation and citrate use, why circuit patency and integrity are important for CRRT, and how and when to use anticoagulation. They also discuss preferred methods for anticoagulation and the parameters that should be monitored for circuit integrity.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Rachel Pessah-Pollack, MD
Host: Peter McCullough, MD
We often think about the cardiovascular, renal, and metabolic (CRM) systems as separate entities, but it's essential that we keep the interconnected nature of these systems top of mind. Drs. Rachel Pessah-Pollack and Peter McCullough are here to review the shared risk factors that contribute to the development and progression of comorbid conditions within these systems, the impact of coexisting conditions of the CRM systems, the continuum of risk, and more.
This is part 1 of a 3-part podcast series.
Copyright © 2021 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
SC-US-69643-C (06/2021)
Guest: Jimmy T. Lee, MD
Guest: Arlene B. Chapman, MD
This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).
Guest: Brett Nowlan, MD
Metabolic dysfunction is the central driver for conditions with some of the highest mortality rates. Identifying this dysfunction early on is essential to preventing disease progression. Dr. Brett Nowlan, a cardiologist at Cottage Grove Cardiology in West Hartford, Connecticut, explains why.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
There is clinical trial-supported evidence for the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure and reduced ejection fraction. RAASi therapy improves both morbidity and mortality outcomes, and its use is now recommended in published guidelines. However, the achievement of target dosing is often limited or interrupted due to the development of hyperkalemia.
In this case-based activity, Drs. Javed Butler and Ileana Piña discuss the importance of optimizing RAASi therapy in patients with heart failure and how the use of potassium binders can help accomplish this goal. They will also review the risks and benefits of potassium binders, in addition to both short- and long-term use of these agents in the treatment of patients with heart failure.
Host: Matthew R. Weir, MD
Guest: Gates B. Colbert, MD, FASN
Guest: Robert Toto, MD
Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect. In this chapterized activity, Drs. Colbert, Toto, and Weir discuss strategies to manage a patient with chronic kidney disease (CKD) and resistant hypertension. Find out who is at risk for HK and explore the use of a potassium binder as both a short- and long-term solution.
Host: John Buse, MD, PhD
Guest: David Wheeler, MB, CHB, MD, FRCP
Recent research has revealed that a type 2 diabetes treatment may help manage chronic kidney disease. Dr. John Buse discusses the use of dapagliflozin in patients with chronic kidney disease with Dr. David Wheeler, a professor of kidney medicine at the University College London in the United Kingdom, and an honorary consultant nephrologist at the Royal Free London NHS Foundation Trust.
Host: Ewa A. Jankowska, MD, PhD, FESC
Hospitalizations due to acute heart failure represent a growing healthcare problem and a large economic burden. Iron deficiency, irrespective of anemia, is prevalent among this population and is associated with a high risk for increased mortality and rehospitalization. Tune in to discover the latest data from the AFFIRM-AHF trial. What does this new information reveal about treatment with intravenous iron in patients with acute heart failure?
Host: Stefan D. Anker, MD, PhD
Guest: Javed Butler, MD, MBA, MPH
Guest: Ewa A. Jankowska, MD, PhD, FESC
Guest: Josep Comin-Colet, MD, PhD
How does treatment of iron deficiency affect outcomes in patients hospitalized for acute decompensated heart failure? This late-breaking video brief reviews the topline results of the AFFIRM-AHF data released at the 2020 American Heart Association Scientific Sessions and provides reactions from several heart failure experts on what these data mean on a global level.
Host: Mikhail Kosiborod, MD
Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.
Guest: Anil Agarwal, MD
How can healthcare professionals at the forefront of the pandemic protect the vascular integrity of COVID-19 patients undergoing acute dialysis procedures? Here to walk us through his process step by step is Dr. Anil Agarwal from the Ohio State University Wexner Medical Center.
Published August 19, 2020
Host: Matt Birnholz, MD
Guest: Anil Agarwal, MD
The emergence of blood clotting and clogged equipment for vascular procedures is a more recent—and troubling—phenomenon that’s emerged from the COVID-19 pandemic. Tune in as Dr. Anil Agarwal from the Ohio State University Wexner Medical Center discusses these two challenges and strategies for overcoming them.
Published August 13, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Dorry Segev, MD, PhD
With organ transplants on pause in the US to free up needed hospital resources, Americans with kidney failure are forced to assume the risks of going to crowded dialysis centers three times a week. Kidney transplant surgeon Dr. Dorry Segev talks with Stephanie Desmon about how the organ transplant community can rethink ways to resume transplants, assess which patients might fare better with risky transplants, and if COVID-19 patients can be organ donors.
Published April 28, 2020
Host: Jennifer Caudle, DO
Guest: Ashira Blazer, MD
Did you know that African Americans are three times as likely to be diagnosed with lupus than other demographic groups? To make matters worse, being diagnosed with lupus doubles their risk of kidney disease, stroke, and heart attacks.
To address this growing health threat among African Americans, Dr. Jennifer Caudle is joined by Dr. Ashira Blazer, Instructor in the Department of Medicine and Rheumatologist at NYU Langone Health, to discuss diagnosis, comorbidities, and various treatment options for your lupus patients.
Correction Note: Dr. Blazer has updated that in the U.S., variation homozygosity for APOL1 is present in 13% of the African American population.
Host: Maurice Pickard, MD
Guest: Bob Mitchell
Quite suddenly, Bob Mitchell became very sick. He would endure three near-fatal episodes of ventricular tachycardia due to a heart muscle comprised of 54% scar tissue, as well as heart surgeries, two harrowing months of waiting on the transplant list for a new heart on life-supporting IV drips (during which time a malignant tumor was detected in his kidney), partial nephrectomy surgery to remove the cancer, another month of waiting, a 12-hour heart and kidney transplant surgery, and 100 days on life support in four different hospitals.
Host Dr. Maurice Pickard talks with novelist Bob Mitchell, author of Time for a Heart-to-Heart: Reflections on Life in the Face of Death about his inspiring story of the triumph of hope in the face of the direst of circumstances.
Host: Shira Johnson, MD
For the first time, Penn Medicine surgeons were able to complete a bilateral hand transplant on a child. The surgical team successfully transplanted donor hands and forearms onto 8-year-old Zion Harvey who, several years earlier, had undergone amputation of his hands and feet and a kidney transplant following a serious infection.
Host Dr. Shira Johnson sits down with Dr. Scott Levin, who led the surgical team and is Chairman of the Department of Orthopaedic Surgery at Penn Medicine. They discuss this remarkable, groundbreaking surgery.
Host: Brian P. McDonough, MD, FAAFP
On this special program, Dr. Brian McDonough speaks with Chrissy McCoog and her father, Lou Antosh, about their collective experience in navigating a topsy-turvy healthcare system through the diagnosis, management, and followup of Chrissy's chronic kidney disease, Focal segmental glomerulosclerosis (FSGS). Ms. McCoog details her nearly 20-year path as patient, and the struggles and triumphs she has witnessed. Mr. Antosh also describes his parental point of view as central advocate for his daughter's health and wellbeing, and the public awareness of FSGS that they are both trying to spread through the nonprofit organization, NephCure.
Guest: George L. Bakris, MD
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown talks with Dr. George Bakris, director of the Hypertensive Disease Unit at the University of Chicago Pritzker School of Medicine, about lipid management in the hypertensive patient and its particular relevance to patients with chronic kidney disease. How do cardiovascular events differ in chronic kidney disease patients compared to the general population? And do statins work in dialysis patients? They discuss these questions and the conclusions of the Study of Heart and Renal Protection (SHARP).
Host: Aaron Carroll, MD
Guest: Mary Maluccio, MD, MPH
While the incidence of many types of cancer in the United States has decreased in recent years, the incidence of hepatocellular carcinoma, secondary to either hepatitis B or cirrhosis, has been on the rise. And, of the treatment options including resection, ablation and transplantation, what tumor characteristics determine treatment and which patients might benefit most from liver transplant? Dr. Mary Maluccio, director of the liver oncology program at Indiana University Health, discusses the advantages of transplant, the length of time that patients generally wait to receive a donor liver and the criteria for donor organs. Hosted by Dr. Aaron Carroll.
Guest: Tim Taber, MD
Host: Aaron Carroll, MD
Patients needing transplantation have two options--receiving an organ from a deceased donor or a living donor. In which cases might living organ donation be a viable option, and what are the advantages to this procedure? Dr. Tim Taber, medical director of the kidney and pancreas transplant program at Indiana University Health, discusses the issue of organ shortages, how organs are allocated and the process of living organ donation. Dr. Aaron Carroll hosts.
Host: Eric Tangalos, MD
Guest: Manjula Kurella Tamura, MD, MPH
How do the processes leading to kidney failure differ for various patient populations? What special considerations should physicians keep in mind when caring for patients in long-term care facilities undergoing dialysis? Dr. Manjula Kurella Tamura, nephrologist and assistant professor of medicine at Stanford University School of Medicine, reviews findings from a study regarding functionality for patients undergoing dialysis. Dr. Kurella Tamura points out that although dialysis may increase longevity, it may not improve quality of life. What is recommended for optimal care of patients with kidney failure? Hosted by Dr. Eric Tangalos.
Guest: David Ward, MD
Host: Steven Edelman, MD
Diabetes is the most common cause of kidney failure. However, most people with diabetes can avoid end-stage kidney disease and minimize their risk of kidney failure with intensive management of diabetes. Join host Dr. Steven Edelman and his guest, nephrologist and professor of medicine at the University of California San Diego, Dr. David Ward as they discuss diagnosis, symptoms, prevention and treatment of diabetic kidney disease.
Host: Mark Nolan Hill, MD
Guest: Sam Bhayani, MD
Robotic surgery has made important in-roads into the fields of cardiac and urologic surgery. Though much of the work in urologic surgery has focused on the prostate, we're now seeing a trend toward the use of robotics in procedures to remove kidney tumors. Given the delicate nature of kidney tissue, these procedures can present considerable technical challenges, but they may also provide better outcomes for our patients with kidney cancer. Dr. Sam Bhayani, assistant professor of surgery and co-director of robotic surgery at Washington University School of Medicine in St. Louis, attributes these improvements to the better views of the tumor targets and a more efficient procedure afforded by the robotic instruments. Dr. Bhayani joins host Dr. Mark Nolan Hill to speak about current trends in robotics and renal cancers.
Guest: Margaret Miller, MD
Host: Lisa Mazzullo, MD
Currently there are no tests available to confirm the diagnosis of preeclampsia in pregnant women. Preeclampsia affects two to 10 percent of pregnancies in the United States and it's the most common and potentially life threatening complication for a pregnant woman and her child. Dr. Margaret Miller, an assistant professor of medicine and obstetrics and gynecology at the Warren Alpert Medical School at Brown University in Providence, Rhode Island, discusses with host Dr. Lisa Mazzullo her research examining possible biomarkers to predict preeclampsia and its possible link to cardiovascular disease later in life.
Guest: Joseph Murray, MD
Host: Martin Samuels, MD
Nobel Prize winner Dr. Joseph E. Murray discusses performing the first successful human kidney transplant, the value of teamwork, the future of the physician-scientist, and the patient side of the equation, in this far-ranging conversation led by host Dr. Martin Samuels.
Guest: Bruce Slaughenhoupt, MD
Host: Jennifer Shu, MD, FAAP
Once considered to be a problem of adulthood, kidney stones are being more regularly documented in children as young as age five. What factors are responsible for the increasing prevalence of this condition, and what can we do to reverse this emerging pattern of childhood kidney stones? Dr. Bruce Slaughenhoupt, assistant professor of urology and co-director of the pediatric kidney stone clinic at the University of Wisconsin School of Medicine, evaluates the clinical implications of this trend with host Dr. Jennifer Shu.
Host: Bruce Bloom, DDS, JD
Guest: Eamonn R. Maher, MD
Guest: John Solly, PhD
Skin lesions, pneumothorax and kidney tumors? Is it Birt-Hogg-Dubé Syndrome? Described in the late 1970s, Birt-Hogg-Dubé was very difficult to recognize until recent molecular genetic testing made the diagnosis of this orphan disease more accurate. What is this disease? What systems does it affect? How do we treat it and what is the hope for the future? Join host Dr. Bruce Bloom and his guests Dr. Eamonn Maher, professor of medical genetics and department head of medical and molecular genetics at the University of Birmingham in the UK, and John Solly, director of the Myrovlytis Trust, a UK charity dedicated to the promotion of research into rare genetic disorders.
Host: Bruce Bloom, DDS, JD
Guest: John Solly, PhD
The worldwide effort to find cures for rare disease is often the work of small organizations such as the the Myrovlytis Trust, a not-for-profit organization in Great Britain dedicated to finding treatments and cures for rare diseases. John Solly, charity manager for the Myrovlytis Trust, talks with host Dr. Bruce Bloom, the rationale for focusing large dollars on diseases affecting a small population and how the Trust is approaching the search for a cure to their first target disease, Birt-Hogg-Dubé Syndrome.
Guest: Luke Probst, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
What is the best method for adjusting drug doses for your patients with kidney disease? Research working to answer this question has produced a series of interesting observations: What are these concepts and how does this help us evaluate the problem at hand? Dr. Luke Probst, a pediatric pharmacy specialist and a clinical assistant professor in the departments of pediatrics and medicine at the State University of New York Upstate Medical University, speaks with host Dr. Charles Turck about the need for accurate dose applications to eschew long-term sequela.
Guest: Luke Probst, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
How do you adjust drug doses in your patients with kidney disease? Two main strategies might come to mind: the Cockcroft-Gault equation or the modified diet in renal disease. Is one more applicable for your patients?Dr. Charles Turck welcomes Dr. Luke Probst, a pediatric pharmacy specialist and a clinical assistant professor in the departments of pediatrics and medicine at the State University of New York Upstate Medical University.
Guest: Helen Shields, MD
Host: Jay Goldstein, MD
Though sodium phosphate preparations for colonoscopy have been around for many years, we've recently encountered an influx of kidney problems related to this procedure. Which patient populations face the greatest risk of nephrotoxicity? How severe are these maladies, and what are possible alternatives for our patients? Host Dr. Jay Goldstein discusses the quality of current colonoscopy preps with Dr. Helen Shields, associate professor of medicine at Harvard Medical School.
Guest: Sarah Tomasello, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
How can we optimize erythropoetic therapy in patients with anemia of chronic kidney disease? How widespread is the problem of hyporesponsiveness to erythropoetic-stimulating agents? Dr. Sarah Tomasello, clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, and a clinical specialist in nephrology at Robert Wood Johnson University Hospital in New Jersey, joins host Dr. Charles Turck.
Guest: Sarah Tomasello, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
How are erythropoietic-stimulating agents (ESA) most helpful for patients with chronic kidney disease? What target levels of iron should clinicians maintain before starting ESA therapy, and what challenges will we encounter in this process? Host Dr. Charles Turck probes these questions and more with Dr. Sarah Tomasello, clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, and a clinical specialist in nephrology at Robert Wood Johnson University Hospital in New Jersey.
Guest: Benjamin Hippen, MD
Host: Maurice Pickard, MD
Dr. Benjamin Hippen speaks about the Iranian system that allows an individual's kidney to be sold by the donor, whom we can also think of as the vendor. Examination has shown that the recipients are on a level playing field and there is no tourism or fraud. The responsibility for recruiting potential vendors becomes separated from the responsibility for approving the vendor's medical and surgical candidacy. But moral concerns in the US may have to be resolved in the future by a hybrid system that combines features of both systems.
Guest: Benjamin Hippen, MD
Host: Maurice Pickard, MD
Dr. Benjamin Hippen reviews the kidney transplantation policy failure in the United States. The cost is now 21 billion dollars in Medicare commitment to end-stage renal disease and 50 percent of those on the transplant waiting list will likely die before receiving an organ. This situation is getting worse by the day. Iran is the only country in the world that has no organ shortage. Is their system of legal organ "vending" worth examining?
Guest: Michael Rudnick, MD
Host: Lee Freedman, MD
How can we protect our patients who have renal insufficiency from a further decline in kidney function when they need a test or procedure that involves the use of intravenous contrast? What type of hydration is most effective? Are certain medications protective? Dr. Rudnick reviews the data on all of these points in this helpful discussion.
Guest: Michael Rudnick, MD
Host: Lee Freedman, MD
Dr. Rudnick reviews the reasons for the rising incidence of contrast-induced renal problems. He outlines the risk factors for "CIN" - both related to procedures and patients - and then comments on the clinical significance of this growing issue.
Guest: Victor Gura, MD
Host: Gary Kohn, MD
Dr. Victor Gura, attending physician at Cedar Sinal Medical Center, and inventor of the wearable kidney, discusses this "holy grail of dialysis", the motivations behind its creation, and the benefits observed in trials thus far.
Guest: John Donoghue, PhD
Host: Gary Kohn, MD
Dr. John Donoghue, Director of the Brain Science Program at Brown, discusses the emerging field of neuroprosthetics and the possibilities of new help for paraplegics and those with advanced neurological diseases.
Guest: John Donoghue, PhD
Host: Gary Kohn, MD
Dr. John Donoghue, Director of the Brain Science Program at Brown, gives us the history and lay-of-the-land in research studies of how the brain controls movement. Are there applications for paraplegics and those with advanced neurological diseases?
Guest: Robert Stanton, MD
Host: Mark Nolan Hill, MD
Kidney disease is on the rise especially amongst diabetics. In this segment Nephrologist, Dr. Robert Stanton talks about the incidence and treatment of diabetic kidney disease.
Guest: Jacob Teitelbaum, MD
Host: Susan Dolan, RN, JD
Join Dr. Jacob Teitelbaum, Director of the Fibromyalgia and Fatigue Centers, based in Dallas, Texas, and author of "From Fatigued to Fantastic," as he discusses the diagnosis and treatment of adrenal insufficiency.
Host: Lee Freedman, MD
Guest: Irene Agodoa, MD
Dr. Agadoa discusses the efforts of the National Medical Association and AMGEN to address the disparities in healthcare for minorities with renal disease.
Guest: Irene Agodoa, MD
Host: Lee Freedman, MD
Dr. Agadoa discusses the increased incidence of renal disease in African Americans and other minority populations and possible interventions to combat this situation
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.
Guest: George L. Bakris, MD
Host: Leslie P. Lundt, MD
Dr. Bakris discusses the relationship of mortality in chronic kidney disease and cardiovascular disease and the role of ejection fraction.
Guest: George L. Bakris, MD
Host: Leslie P. Lundt, MD
Dr. Bakris discusses how mild to moderate kidney disease is associated with increased risk for cardiovascular disease.
Guest: George L. Bakris, MD
Host: Leslie P. Lundt, MD
Dr. Bakris explains how kidney disease is a silent killer.
Guest: Michael Kraus, MD
Host: Matthew J. Sorrentino, MD, FACC, FASH
Dr. Michael Kraus discusses the current treatment options for ESRD and presents the current enthusiasm for considering increased frequency dialysis to improve a patient's quality of life with dialysis.
Guest: Michael Kraus, MD
Host: Matthew J. Sorrentino, MD, FACC, FASH
The number of patients with end-stage renal disease is growing rapidly. Dr. Michael Kraus, Nephrologist at Indiana University, reviews the statistics and ways to prevent ESRD in at-risk patients.